Interestingly, while combination IL-7 ALT + αPD-1 therapy exhibited a limited survival benefit in the CT2AvIII glioma model (Figure 2D), greater efficacy was observed in mice bearing more immunogenic GL261 gliomas (35) (Figure 2F). This evidence concerns the gene IL7 and central nervous system cancer.